NTHIHealthcare · BiotechnologyThe 4 Wall Street analysts covering NeOnc Technologies Holdings, Inc. hold a median 12-month price target of $18 — +435.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 23 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores NeOnc Technologies Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (74): Smaller than most of the companies we track.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NTHI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +435.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Roth Capital | Initiates | Buy | $20 |
| 8 Sept 2026 | BTIG | Reiterates | Buy | $15 |
| 8 Sept 2026 | BTIG | Reiterates | Buy | — |
| 26 May 2026 | BTIG | Reiterates | Buy | $15 |
| 26 May 2026 | BTIG | Reiterates | Buy | — |
| 19 May 2026 | Alliance Global Partners | Initiates | Buy | $13 |
| 19 May 2026 | Alliance Global Partners | Initiates | Buy | — |
| 18 May 2026 | Maxim Group | Initiates | Buy | — |
| 24 Apr 2026 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NTHI appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, NeOnc Technologies Holdings, Inc. returned −60.8% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 1% of US stocks
Cheaper than 97% of US stocks
Cheaper than 71% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeOnc Technologies Holdings, Inc. has a market value of $94.2M and an enterprise value of $82.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$47.2M.
Free cash flow in the twelve months to 30 June 2026: −$21.7M.
Trailing P/E: −1.0×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NeOnc Technologies Holdings, Inc. employs 5 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeOnc Technologies Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeOnc Technologies Holdings cleared several key resistance levels on strong trading volume, following a recent test of lows near $2.50. The report describes the move as a potentially important technical signal.
Why it matters — NTHI watchers may note the reported breakout and trading volume as a change in the stock’s recent chart pattern.
NeOnc Technologies Holdings (NASDAQ: NTHI) is set to share its brain cancer story on Fox Business Network. The announcement links the appearance to several developments drawing attention to the clinical-stage biotech.
Why it matters — NTHI watchers may note the planned media appearance as the company’s brain cancer work and recent developments receive attention.
NeOnc Technologies said it will be featured on Health Uncensored with Dr. Drew in a segment about non-invasive approaches to delivering investigational therapies to brain tumors.
Why it matters — The appearance will discuss an approach related to the company's development of therapies for central nervous system cancers.
NeOnc is preparing for an upcoming FDA meeting, while its work in Abu Dhabi is highlighted alongside a new research MoU and a senior banking appointment. The excerpt frames these developments as part of the company’s development story.
Why it matters — NTHI watchers may note the forthcoming FDA meeting and the additional activities mentioned as context for the company’s development efforts.
The headline says NeOnc is deepening research ties in Abu Dhabi as its brain cancer story progresses. The excerpt provides no details about the research arrangement or developments.
Why it matters — NTHI watchers may follow the reported Abu Dhabi research ties as part of the company’s brain cancer-related activity.
The 4 Wall Street analysts covering NeOnc Technologies Holdings, Inc. have a median 12-month price target of $18, with estimates ranging from $13 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering NeOnc Technologies Holdings, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Oct 2026, NeOnc Technologies Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +435.2% from the last close, and Ticker Nerd's factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeOnc Technologies Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTHI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $20 over the next 12 months.
NeOnc Technologies Holdings, Inc. returned -60.8% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers and other intracranial malignancies.
The most recent item we track (GlobeNewsWire, 23 Oct 2026): "NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue". NeOnc Technologies Holdings cleared several key resistance levels on strong trading volume, following a recent test of lows near $2.50. The report describes the move as a potentially important technical signal.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers and other intracranial malignancies. Its current pipeline centers on NEO100, a purified form of perillyl acid being studied in Phase IIa trials, and NEO212, an oral drug candidate evaluated in Phase I/II trials for primary and secondary brain cancers, including glioblastoma, meningioma, and high-grade gliomas. The company is also developing technologies designed to improve delivery of therapeutics across the blood-brain barrier, a key challenge in treating brain diseases. NeOnc Technologies Holdings, Inc. operates within the biotechnology sector and serves the specialized oncology market with a focus on hard-to-treat brain tumors and related central nervous system conditions.
CEO Mr. Amir Farrokh Heshmatpour · 5 employees · United States · https://www.neonc.com
